Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease [Corrigendum]
Hager K, Baseman AS, Nye JS, Brashear HR, Han J, Sano M, Davis B, Richards HM. Neuropsychiatr Dis Trea. 2014;10:391–401. On page 393, Figure 1, “Maintenance period (month 6 to 24)” should be “Maintenance period (month 4 to 24)”; &...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/09ce8a88547845a3adad92e246cc5c0a |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Hager K, Baseman AS, Nye JS, Brashear HR, Han J, Sano M, Davis B, Richards HM. Neuropsychiatr Dis Trea. 2014;10:391–401. On page 393, Figure 1, “Maintenance period (month 6 to 24)” should be “Maintenance period (month 4 to 24)”; “– Gal at stable dose (at least 18 mg/day) as achieved on day 84c” should be “– Gal at stable dose (at least 16 mg/day) as achieved on day 84c”. Read the original article |
|---|